Erik Petter Wingstrand
Voorzitter bij T-Bolaget AB
Oorsprong van het eerstegraads netwerk van Erik Petter Wingstrand
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Resistentia Pharmaceuticals AB
 Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.
16
| Extinct | Pharmaceuticals: Major | 16 |
Internetmedicin Holding AB
2
| Private Company | 2 | |
T-Bolaget AB
 T-Bolaget AB Financial ConglomeratesFinance T-Bolaget AB engages in investment and trading of securities, for a limited and closed group of owners. The company was founded on December 15, 1958 and is headquartered in Gothenburg, Sweden.
2
| Private Company | Financial Conglomerates | 2 |
Jumperfabriken Sweden AB
 Jumperfabriken Sweden AB Apparel/Footwear RetailRetail Trade Jumperfabriken Sweden AB is a Swedish company that sells men's and women's clothing and accessories through an online platform.
1
| Private Company | Apparel/Footwear Retail | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Erik Petter Wingstrand via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Bath | College/University | Undergraduate Degree | |
| MEDIVIR AB | Pharmaceuticals: Major | Chairman President | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Stockholm School of Economics | College/University | Graduate Degree Graduate Degree | |
| University of Uppsala | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chairman Founder | |
| University of Stockholm | College/University | Graduate Degree Masters Business Admin | |
| ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BOULE DIAGNOSTICS AB | Medical Specialties | Director/Board Member | |
Cancer Research Technology Ltd.
 Cancer Research Technology Ltd. Medical SpecialtiesHealth Technology Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member | |
| ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
| Royal Institute of Technology | College/University | Graduate Degree Doctorate Degree | |
| Henley Management College | College/University | Masters Business Admin Masters Business Admin | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
| University of Gothenburg | College/University | Corporate Officer/Principal Doctorate Degree | |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Investment Managers | Private Equity Investor Private Equity Investor | |
Takara Bio Europe AB
 Takara Bio Europe AB Miscellaneous Commercial ServicesCommercial Services Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BIOARCTIC AB | Pharmaceuticals: Major | Director/Board Member | |
| BICYCLE THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Healthcap 1999 GP AB
 Healthcap 1999 GP AB Investment Banks/BrokersFinance Part of Odlander, Fredrikson & Co. AB, Healthcap 1999 GP AB is a company that manages and trades securities. The company is based in Stockholm, Sweden. | Investment Banks/Brokers | Director/Board Member Director/Board Member | |
Ryda Bruk AB
 Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The company is based in Heby, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer | |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| XINTELA AB | Biotechnology | Director/Board Member | |
Atopix Therapeutics Ltd.
 Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Ceffort AB
 Ceffort AB BiotechnologyHealth Technology Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden. | Biotechnology | Director/Board Member | |
QuiaPEG Pharmaceuticals AB
 QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Founder | |
F-Star Beta Ltd.
 F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
| QUIAPEG PHARMACEUTICALS HOLDING AB | Biotechnology | Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
F-star Therapeutics Ltd.
 F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Investment Managers | Consultant / Advisor | |
F-star Biotechnology Ltd.
 F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Zweden | 29 |
| Verenigd Koninkrijk | 12 |
| Verenigde Staten | 5 |
| Oostenrijk | 3 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 9 |
| Finance | 6 |
| Commercial Services | 6 |
Operationeel
| Director/Board Member | 179 |
| Corporate Officer/Principal | 42 |
| Chairman | 21 |
| Independent Dir/Board Member | 18 |
| Private Equity Investor | 12 |
Sterkste connecties
- Beurs
- Insiders
- Erik Petter Wingstrand
- Bedrijfsconnecties
